Barclays Lowers Stock Rating for Terns Pharmaceuticals Amid Merck Deal
Published on 3/30/2026
AI Summary
Barclays has downgraded the stock rating for Terns Pharmaceuticals, citing the recent deal with Merck. This change could influence investor sentiment and trading volumes for Terns Pharmaceuticals as the market reacts to the adjustment in outlook. The specifics of the rating change were not disclosed in the report. Analyst ratings can significantly impact stock prices and market positioning.
Related News
Earnings
Versant (VSNT) Stock Rises Nearly 10% Post Q1 Report with Key Metrics
May 14
Earnings
Intuitive Machines (LUNR) Earnings Miss by $0.19, Revenue Falls Short
May 14
Earnings
Expensify (EXFY) Q1 2026 Results Miss Expectations, Shares Rebound
May 14
Earnings
Honda (HMC) Reports $9 Billion EV Writedown Impacting Financials
May 14